Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329730 | 0.87 | PTGES2 (0.45) | PTGS2PTGES2BTKSCN9A | |
| SCHEMBL23093438 | 0.80 | PTGS2 (0.48) | PTGS2HDAC6PTGS1 | |
| SCHEMBL29802445 | 0.80 | PTGS2 (0.48) | PTGS2HDAC6PTGS1 | |
| SCHEMBL2329728 | 0.79 | PTGES2 (0.49) | PTGES2BTKKCNH2 | |
| SCHEMBL19243065 | 0.78 | THRB (0.54) | PTGS2HDAC6 | |
| SCHEMBL6997658 | 0.78 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL18255986 | 0.78 | NPC1 (0.54) | BTK | |
| SCHEMBL12498066 | 0.78 | BTK (0.46) | F2RL3PTGES2BTK | |
| SCHEMBL13996079 | 0.78 | RAB9A (0.56) | PTGES2BTKKCNH2 | |
| SCHEMBL1360819 | 0.77 | RAB9A (0.60) | PTGES2HDAC6BTKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765039-B2 | Biaryl derivatives as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20140140956-A1 | BIARYL DERIVATIVES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140956-A1 | BIARYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRDT, BRD3, BRD4 | PTGS2 3702/4885F2RL3 3174/4885PTGES2 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.